VEGFA and endometrial cancer: Since VEGF is a critical downstream effector of hypoxia-driven HIF-1α activation and a key driver of neovascularization in endometrial cancer, its marked reduction suggests that BA and GEM may impair the vascular supply essential for tumor growth and survival.